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ABSTRACT: Nuclear suspensions of 42 prostate carcinoma specimens obtained at sur- 
gery were used to investigate loss and gain of chromosomes 1, 18, and Y by fluorescence in 
situ hybridization (FISH) with centromere-specific probes. The outcome of FISH analysis 
was correlated with clinical parameters and the relationship between DNA-FCM (ploidy at 
cellular level) and FISH (ploidy of individual chromosomes) was assessed. 
Significant loss of chromosomes 1 and 18 was infrequent (respectively, three and five 
cases), but 53% of the tested specimens showed loss of Y. Loss was not correlated with DNA 
ploidy. Significant gain occurred in 36% (chromosome l), 63% (chromosome 18), and 28% 
(Y) of the specimens. Gain of chromosome 18 was shown in DNA diploid (7114) and aneu- 
ploid tumors (18/26), while gain of chromosomes 1 and Y was nearly restricted to DNA 
aneuploid specimens. Significant unbalance between these chromosomes occurred in 11 
cases. Most cases which had significant gain of chromosome 1 or 18 showed trisomic as well 
as tetrasomic cells. Simultaneous loss of some and gain of other investigated chromosomes 
is suggestive of clonal heterogeneity and/or multiclonality. This was observed in eight 
tumors. 
Correlation between DNA-FCM and FISH was best for the Y chromosome. DNA-FCM 
showed more aberrant histograms with increasing stage and grade of tumors. The presence 
of numerical aberrations of the investigated chromosomes however, seemed independent of 
clinical grade or stage. 
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INTRODUCTION 
In prostate cancer (PC), investigation of chromo- 
somal aberrations might provide clues to the changes 
that play an important role in the origin and progres- 
sion of this tumor. Classical cytogenetic studies, 
which mostly made use of short-term tissue culture 
to obtain an adequate number of metaphase spreads, 
have shown chromosomal aberrations in only a mi- 
nority of cases 11-51. Recurrent structural changes 
were reported for chromosomes 1, 2, and 7 (p and q 
arm), 3p, 6p, 8p, lOq, 13q, 15q, and 16q. Whole chro- 
mosome gain of nos. 7, 14’20, and 22 and loss of one 
homolog of nos. 1, 2,4, 5, and Y were most common 
[6]. However, most cases showed normal diploid 
karyotypes, probably due to selective isolation and 
preferential growth of normal epithelial cells [7, 81. 
An alternative method to study chromosomal ab- 
normalities is by measurement of the total DNA con- 
tent of individual cells using DNA flow cytometry 
(FCM). Unlike cytogenetic analyses, such studies 
showed that most prostate tumors had one or more 
aneuploid cell populations [9-121, which was associ- 
ated with an unfavorable outcome of the disease. The 
cytogenetic sensitivity of DNA-FCM is limited how- 
ever: numerical or structural changes of individual 
chromosomes remain undetected. 
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In the present study, we used a third technique for 
the investigation of chromosomal changes, namely 
fluorescence in situ hybridization (FISH) with chro- 
mosome-specific DNA probes [13]. FISH has the ad- 
vantage over classical cytogenetics that tissue culture 
is not needed, because signals can be detected in in- 
terphase nuclei as well as in metaphases. Further- 
more, the larger number of cells that can be analyzed, 
allows the discrimination between random abnormal- 
ities (which are frequently observed in karyotyping 
studies of PC [l, 2, 41) and clonal changes. We have 
shown before that FISH on fresh nuclear suspensions 
of PC specimens is feasible [a]. FISH studies with 
centromere-specific probes investigate the copy num- 
ber of particular chromosomes, to establish whether 
the chromosome copy number is simply a reflection 
of the total ploidy [14] or an indication for gene loss, 
regardless of whether a chromosome is lost (loss of 
one homolog) or gained (chromosomal duplication 
driven by gene loss on one homolog). 
We report here the frequencies of loss and gain of 
chromosomes 1, 18, and Y. The rationale for studying 
these chromosomes was: 1) for chromosome 1 not 
only structural abnormalities but also whole chromo- 
some loss and gain have been reported in PC [6], 2) in 
two separate studies loss of heterozygosity (LOH) 
was reported on the long arm of chromosome 18 [15, 
161, 3) loss of Y was frequently found in PC [l-3, 5, 
171, sometimes even as the only aberration. The re- 
sults of these studies were correlated with tumor 
grade and stage, and DNA-FCM. 
MATERIALS AND METHODS 
Tissue Processing 
Forty-two prostatic adenocarcinoma specimens 
were studied, obtained at radical prostatectomy (N = 
25), transurethral resection (TUR; N = 13), or pelvic 
lymph node dissection (N = 4). Suspected carcinoma 
tissue was excised and, whenever the amount of tis- 
sue allowed, cut with scissors into two parts. One 
part was cut into several smaller fragments, snap fro- 
zen in liquid nitrogen, and stored at -80°C for later 
use. To the other part approximately 0.5 ml of phos- 
phate buffered saline (PBS) was added and the tissue 
pieces were further minced with a scalpel into a sus- 
pension of small cell clumps and single cells. The 
clumps were discarded after sedimentation for 3-5 
min in 5 ml of PBS. The supernatant was centrifuged 
and the resulting pellet washed and resuspended in 
PBS. From this cell suspension a sample was stored 
for DNA-FCM. The rest of the cell suspension was 
incubated with hypotonic solution (0.075 M KCI) for 
10 min at 37°C and fixed in methanol/acetic acid (3:l). 
Fixed cells were stored in methanol at -20°C until 
used for FISH. The above described procedure for 
tissue processing and fixation of nuclei gave good 
results with both primary tumor tissue and lymph 
node metastases (LM). As nuclei from TUR tissue 
tended to coagulate in suspension, an additional sed- 
imentation step at unit gravity was performed with 
these preparations. 
Histology was taken from adjacent tissue, in be- 
tween the immediately processed sample and the 
sample for storage. From a paraffin section of each 
tumor, grade, stage, and percentage of tumor cells 
were assessed. The mean percentage of tumor cells in 
the sections was 56.3 2 22.1% (range 25-95%). Spec- 
imens with less than 25% tumor cells were not in- 
cluded in the study. 
For control purposes, leukocytes were obtained 
from each patient. A sample of peripheral blood in 
heparin was mixed with a 3% solution of high mo- 
lecular weight dextran in saline (one part on two to 
three parts of blood). The erythrocytes were allowed 
to sediment at unit gravity for 15-30 min and the 
leukocytes in the supernatant were washed once 
with RPMI medium by centrifugation. The enriched 
leukocytes were then suspended in fetal calf serum 
with 12% dimethylsulfoxide and stored in liquid ni- 
trogen. 
DNA-FCM Procedure 
Stored samples were processed for DNA-FCM as 
described [7]. The ploidy of the different peaks in 
histograms from tumor samples was calculated from 
their position, relative to the GO/G1 peak (C-value = 
2) in a histogram of cultured normal diploid prostate 
fibroblasts. Diploid: C = 1.9-2.2; hypodiploid: C 5 
1.8; hyperdiploid: C = 2.3-2.7; triploid: C = 2.8-3.4; 
tetraploid: C = 3.5-4.2. Tumors showing more than 
10% of the nuclei to be in the tetraploid range, rep- 
resenting diploid G2M phase cells as well as tetra- 
plolid tumor cells, were considered to comprise a sig- 
nificant population of tetraploid tumor cells [7]. 
FISH Procedure 
The chromosome-specific probes used were: PUC 
1.77 [IS], hybridizing to SATIII repeats on the peri- 
centromeric heterochromatin region of chromosome 
1; L1.84 [19], hybridizing to alphoid repeats on the 
centromere of chromosome 18; and DYZ3 [20], hy- 
bridizing to SATIII repeats on the centromere of the Y 
chromosome. 
Hybridization and detection were performed as 
described by Pinkel et al. [21] with modifications. In 
short, the probe was labeled with Bio-ll-dUTP by 
nick translation. Slides with fixed nuclei were pre- 
treated with RNase and postfixed with formalde- 
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TABLE 1. Values of BPH Specimens Obtained by Fish Analysis* 
Chromosome cut-off Normal cut-off 
no. No. LOSSa (% copy no. Gain” (% gain)’ 
1 
18 
Y 
15 3.3 2 2.5 8.3 93.7 +- 3.5 2.8 * 3.3 9.4 
12 2.4 2 2.3 7.0 96.0 2 2.6 1.7 5 1.0 3.7 
11 0.9 +- 1.2 3.3 94.2 t 1.9 2.6 +- 2.8 8.2 
“At least 300 nuclei were scored per chromosome and per sample. 
”All numbers are average percentages -C S.D. Loss: % O+ 1 spot for chromosomes 1 and 18,O spots for 
Y; normal copy number: 2 spots for chromosomes 1 and 18, 1 spot for Y; gain: >2 spots for chromo- 
somes 1 and 18, >l spot for Y. 
bAverage + 2 x S.D. 
hyde. Hybridization of the probe to the nuclei (15 ng 
probe per slide) occurred during overnight incuba- 
tion at 37°C in a moist chamber in 65% formamide. 
Slides were subsequently washed in 60% forma- 
mide/2 X SSC (3 x 5 min), 2 x SSC (3 x 5 min) both 
at 40”C, followed by 3 x 5 min in 0.1 x SSC at 60°C, 
5 min in 2 x SSC, and 5 min in 4 x SSC/O.O5% Tween 
at 20°C. Detection of hybridized sequences was with 
Avidin-FITC (incubation: 20 min at 37”C), followed by 
biotinylated goat a-Avidin (incubation: 30 rnin at 
37°C) and a second Avidin-FITC incubation. Nuclei 
were counterstained with propidium iodide in anti- 
fade solution. The number of spots per nucleus, rep- 
resenting the number of centromeric regions of a re- 
spective chromosome, was counted at X 1,250 
magnification on a Zeiss Axiophot fluorescence mi- 
croscope equipped with a FITC filter combination. 
Evaluation and Statistics 
Due to the limited amount of tissue available, hy- 
bridization with the probe for Y was not possible with 
10/42 specimens. In two specimens the hybridization 
with the probe for chromosome 18 was not evaluable. 
For the evaluation of FISH signals we used the 
criteria of Hopman et al. [22]: a) nuclei should be 
intact and should not overlap; b) FISH signals within 
one nucleus should be completely separated (split or 
paired spots should be counted as one) and of the 
same intensity. When these criteria could not be met, 
such nuclei were excluded from counting. When 
more than 10% of the nuclei on a slide had to be 
excluded, the hybridization was repeated. When 
there were more than 5% nuclei with one spot on a 
slide, the hybridization was also repeated. At least 
300 nuclei were scored per sample and per probe. 
Aneusomy was defined to be significant when the 
percentage of nuclei with numerical changes differed 
from the average percentage in benign prostatic hy- 
perplasia (BPH) specimens by at least 2 times S.D. 
(Table I). Dependent on the number of nuclei 
counted, the Kolmogorov-Smirnov (KS) test [23] 
gives a minimally required discrepancy percentage 
for two observations. When two observations (in this 
study counts of spots from probes of two different 
chromosomes) differed more than the discrepancy 
percentage, these observations were considered sta- 
tistically significant. 
RESULTS 
Frequency of Chromosomal Aberrations in 
BPH Specimens 
The frequency of numerical aberrations of chromo- 
somes 1, 18, and Y was determined in BPH speci- 
mens in order to gain insight in: 1) the sensitivity of 
the hybridization reaction for each probe, and 2) to 
assess cut-off percentages for significant gain and loss 
of each investigated chromosome. 
Sensitivity was considered good for chromosomes 
1 and 18 and very high for chromosome Y (see Table 
I, column headed “loss”). Extra spots (see Table I, 
column headed ”gain”) were scored with an accept- 
able frequency for chromosome 18 (range 0.3-3.5%), 
but the frequencies for chromosomes 1 (range 0.8- 
12.7%) and Y (range 2.5-7.2%) were higher. 
The distribution of hybridization spots in nuclei 
from BPH specimens was used to calculate the cut-off 
values for significant gain or loss of each of the three 
chromosomes investigated in PC specimens (see Ta- 
ble I). 
Frequency of Chromosomal Loss and Gain 
in PC Specimens 
Figure 1A and Table 11 show the percentages of 
nuclei with less than two copies (for chromosomes 1 
and 18, respectively) and less than one copy (Y chro- 
mosome), scored for each tumor individually. The 
average percentages were 3.1 Ifr 2.9 (l), 3.6 ? 3.2 (18), 
and 7.9 5 17.6 (Y). Note that in one tumor the Y 
chromosome was entirely lost (PC320, see also Table 
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Fig. I. A: Distribution of percentages of mono-nullisomic nuclei, and B: polysomic nuclei for 
chromosomes I, 18, and Y. Open symbols, DNA diploid; closed symbols, DNA aneuploid; solid line, 
average percentage. 
11). Since no loss of Y was observed in cultured pe- 
ripheral lymphocytes of this patient, this loss was 
considered tumor specific. 
Chromosome loss above cut-off level was infre- 
quent for chromosomes 1 and 18, as it occurred in 
only 3/42 tumors for chromosome 1 and in 5/40 tu- 
mors for chromosome 18 (see Table 11). Significant 
loss of the Y chromosome however, occurred in 17/32 
tested specimens (53%; see Table 11). Unbalanced 
loss, as determined by the KS test, occurred in four 
samples. In each of these cases, the Y chromosome 
was involved. In one case (PC320), also chromosome 
18 was underrepresented. Hypodiploid populations 
(by DNA-FCM) were not detected in either of these 
tumors. 
Figure 1B and Table I11 show the frequencies of 
polysomy of chromosomes 1, 18, and Y in the inves- 
tigated tumors. Table I11 also shows the percentages 
and C-values of the aneuploid cell populations deter- 
mined by DNA-FCM. The average percentages were, 
respectively, 4.0 5 3.6, 4.6 ? 4.2, and 5.6 5 3.0 for 
chromosomes 1, 18, and Y. Using the BPH values as 
a reference (see above), we observed significant gain 
in 16/42 (38%) cases for chromosome 1 and in 25/40 
(63%) cases for chromosome 18. Significant gain of Y 
was less common: 9/32 tumors (28%). Two diploid 
tumors each showed gain of chromosomes 1 (PC288 
and PC323) and Y (PC323 and PC360), while gain of 
chromosome 18 occurred in 7/14 diploid tumors. In 
7/32 tumors gain was homogeneous, i.e., all three 
chromosomes showed significant polysomic popula- 
tions (PC269, PC270, PC289, PC290, PC323, PC342, 
and PC351). Significant unbalance among chromo- 
somes 1, 18, and Y, as determined by the KS test, 
occurred in nine tumors (PC288, PC290, PC291, 
PC292, PC301, PC342, PC344, PC354, and PC362). 
Populations of penta- and/or hexasomic nuclei of 
21% were found in PC269, PC289, PC290, and PC291 
for chromosome 1, PC269 and PC354 for chromosome 
18, and PC269 and PC290 for the Y chromosome (see 
also Fig. 2D). In PC301 and PC353 (both DNA dip- 
loid), loss as well as gain of chromosome 18 was 
found. Simultaneous loss and gain of chromosome 1 
was found in PC202, whereas simultaneous loss and 
gain of chromosome Y was found in PC289, PC290, 
PC296, PC342, and PC360. 
From four patients two tissue samples were ob- 
tained. From one of these the samples were obtained 
from the primary tumor (PC256) and from a local re- 
currence, 34 months after radical prostatectomy 
(PC384). FCM and FISH results of these samples were 
comparable; in both samples an equal percentage of 
aneuploid cells was present and chromosome 18 
showed a population of polysomic cells. From three 
other patients a lymph node metastasis (LM) and a 
sample from the primary tumor at palliative surgery 
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TABLE II. Loss of Chromosomes I ,  18, and 
Y Using FISH* 
% of nulli-monosomic nuclei 
for target chromosome 
202 
288” 
289 
290“ 
295 
296 
301 
303 
308 
320” 
329 
342 
343 
353 
359” 
360 
371 
384 
395 
396 
8.3 
0.0 
-
0.6 
0.4 
0.7 
3.4 
13.3 
1.3 
-
0.8 
6.2 
2.4 
2.0 
9.0 
2.7 
-
5.4 
3.5 
6.5 
7.0 
6.3 
3.0 
4.8 
4.2 
0.0 
0.6 
14.2 
6.4 
-
9.4 
NE 
-
0.7 
9.5 
4.4 
2.9 
3.8 
8.6 
NE 
3.2 
2.8 
1.4 
7.3 
1.6 
-
-
-
11.2 
11.3 
-
-
6.4 
15.5 
ND 
-
-
4.9 
ND 
-
11.2 
3.4 
-
-
100 -
9.2 -
3.7 
4.1 
ND 
-
-
15.2 
4.6 
5.7 
7.2 
7.2 
4.9 
-
-
-
-
-
-
*Underlined percentages are above cut-off values. ND, not deter- 
mined; NE, not evaluable. For DNA-FCM results of these samples, 
see Table 111. 
“Unbalanced chromosome loss. 
(TUR) were available. One of these patients showed a 
high percentage of polysomy for chromosome 18 in 
the TUR material (PC301), but not in the LM (PC236), 
while FCM results were comparable in both samples. 
Another patient showed no difference with FISH, 
while FCM was different (PC295 and PC320). The 
third patient showed complex, but different FCM in 
both samples and a profound dissimilarity with FISH 
(PC269 and PC291). 
Correlation Between DNA-FCM and FISH Results 
In 10/14 tumors which showed a diploid DNA- 
FCM histogram, significant chromosomal aberrations 
were found (Tables 11, 111). One specimen (PC323) 
showed polysomy for all three chromosomes. Signif- 
icant chromosomal aberrations were detected in 26/28 
tumors that were aneupioid by DNA-FCM. In most 
aneuploid tumors the percentage of aneuploidy, de- 
termined by DNA-FCM, was higher than the per- 
centage of aneusomic nuclei. This was true for all 
three chromosomes. Only in two cases (PC362 and 
PC292) the percentage of polysomy found for chro- 
mosome 1 was two times higher than the percentage 
of aneuploid cells, as determined by FCM. This was 
not found for either chromosome 18 or Y. 
When polysomy of chromosomes 1, 18, and/or Y 
was detected, in nearly all cases trisomic as well as 
tetrasomic nuclei for chromosomes 1 and 18, and di- 
and trisomic nuclei for the Y chromosome were found, 
irrespective of whether the total DNA content was 
DNA-tetraploid (PC236-384 in Table 111), DNA-trip- 
loid (PC202-371), or otherwise aneuploid (PC269- 
396). Figure 2 shows the spot distributions of chro- 
mosomes 1, 18, and Y for representative tumors with 
different ploidy patterns. Six DNA histograms of PC 
specimens showed populations of hypodiploid cells 
(PC269, PC292, PC295, PC306, PC308, and PC396; see 
Table 111). PC295, PC308 and PC396 showed loss of a 
chromosome (see Table 11). 
Figure 3 shows the relationship between the per- 
centage of aneuploid nuclei found with DNA-FCM 
and the percentage of polysomic nuclei found with 
FISH. The correlation between DNA-FCM and FISH 
of chromosomes 1 and 18 was about equal (respec- 
tively, 0.531 and 0.529), but the correlation between 
DNA-FCM and polysomy for the Y chromosome was 
better (r = 0.78). All correlations were highly signif- 
icant ( P  < 0.0005). 
Relationship of Stage and Grade With Numerical 
Aberrations and Ploidy 
Aberrations of chromosomes 1, 18, and/or Y were 
equally distributed over all stages and grades, while 
with increasing grade or stage FCM showed more 
aberrant histograms (see Tables IV, V). 
DISCUSSION 
We investigated the frequencies of loss and gain of 
chromosomes 1, 18 and Y by FISH and the total 
ploidy by DNA-FCM in the same nuclear suspension, 
obtained from tissue ‘of patients with clinically evi- 
dent PC. These three chromosomes are each, in one 
way or another, involved in the genetics of PC (see 
below). 
Significant loss of chromosomes 1 and 18 was in- 
frequent, and was not correlated with detectable loss 
of total DNA. Due to the high sensitivity of hybrid- 
ization of Y in BPH specimens, the cut-off value was 
very low, so 17/32 PC specimens showed significant 
loss of Y. However, six of these tumors showed a loss 
percentage below 5%. The biological significance of 
such small subpopulations (15%) is presently un- 
known; clonal progression is a possibility, but tech- 
nical artefacts cannot be completely excluded. 
Significant gain of chromosomes 1 and Y was 
largely restricted to DNA aneuploid tumors. Around 
one third of the DNA aneuploid tumors showed gain 
286 Konig et al. 
TABLE 111. Gain of Chromosomes I, 18, and Y and FCM Results" 
FCM 
% of polysomic Major aneuploid Other aneuploid 
nucleia populationb population' 
PC no. 1 18 Y % C % C 
285 
28gd 
301dTe 
323 
329 
340 
341 
352 
353 
357 
360 
382 
389 
395 
236' 
256" 
270 
286 
289 
303 
355 
362d 
384' 
202 
290d 
291dTe 
296 
318 
320' 
342d 
343 
351 
354d 
359 
371 
269' 
292d 
295" 
306 
308 
344d 
396 
7.0 
10.0 
2.8 
10.0 
3.9 
1.0 
0.1 
1.1 
7.3 
4.2 
0.3 
1.5 
8.3 
2.0 
4.1 
6.6 
23.6 
10.0 
19.9 
33.6 
24.2 
28.4 
7.8 
9.6 
33.0 
32.0 
3.4 
5.8 
2.3 
23.8 
1.8 
12.9 
2.3 
10.3 
4.9 
19.1 
-
-
-
-
-
-
-
-
-
-
-
-
_I 
_I 
-
17.6 
0.9 
6.8 
7.2 
4.0 
0.4 
-
11.0 
2.3 
9.3 
9.3 
4.4 
1.4 
0.4 
2.0 
5.7 
0.4 
3.4 
4.0 
13.5 
0.9 
2.5 
6.8 
27.0 
14.0 
18.7 
NE 
21.2 
-
-
-
-
-
-
-
-
-
-
-
-
6.6 
9.9 
9.5 
20.4 
-
-
-
33.3 
6.8 
3.2 
2.3 
7.4 
2.0 
10.6 
22.9 
NE 
1.7 
23.0 
-
-
-
-
-
-
8.7 
1.4 
9.3 
3.7 
17.9 
0.4 
-
__ 
-
6.9 
4.8 
ND 
9.5 
5.1 
ND 
1.0 
1.8 
ND 
ND 
8.7 
4.2 
0.0 
4.4 
3.0 
5.6 
25.6 
ND 
11.3 
5.1 
4.6 
5.3 
5.3 
8.1 
16.3 
2.8 
9.1 
ND 
0.0 
24.7 
0.7 
13.0 
4.4 
5.7 
3.5 
10.8 
-
-
-
-
-
-
-
-
-
ND 
ND 
ND 
4.7 
ND 
1.8 
7 
6 
8 
7 
9 
7 
2 
6 
6 
7 
3 
0 
9 
4 
11 
15 
70 
11 
8 
10 
37 
9 
14 
25 
45 
38 
8 
17 
15 
81 
22 
34 
46 
29 
12 
59 
69 
38 
77 
66 
54 
94 
3.9 
3.5 
3.8 
3.5 
3.0 
3.1 
3.4 
2.9 
3.3 
3.0 
3.6 
3.9 
3.8 
4.0 
4.0 
3.8 
3.6 
3.6 
3.8 
3.6 
3.6 
3.8 
3.2 
3.2 
3.1 
2.9 
3.3 
3.0 
3.0 
2.9 
3.1 
2.9 
3.4 
3.4 
2.2 
- 
1.8 
1.5 
1.8 
1.7 
2.6 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
10 
0 
3 
0 
0 
5 
0 
0 
15 
18 
29 
6 
9 
0 
10 
0 
0 
7 
3 
4 
24 
8 
9 
9 
10 
3 
3 
4 
9 
1.6-2.0 6 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
_. 
- 
- 
4.8 
4.4 
- 
- 
- 
>4 
- 
- 
3.6 
5.3 
5.4 
3.8 
>4.2 
4.7 
- 
- 
- 
4.4 
4.0 
1.7 
3.6 
5.8 
3.5 
3.9 
3.2 
3.5 
3.1 
3.4 
3.6 
>4 
~ 
*PC numbers are listed chronologically, but are grouped according to the main aneuploid populabon 
detected by FCM. ND, not determined; NE, not evaluable. Underlined percentages are above cut-off 
values. 
"For chromosomes 1 and 18: percentage of nuclei >2 spots, for Y: percentage of nuclei >1 spot. 
b,'Aneuploid + diploid (1.9-2.2); ( = 2  = GO/G1 peak position of normal cells) major population: with 
highest percentage 
dunbalanced chromosome gain. 
ePC236 and PC301, PC256 and PC384, and PC295 and PC320 are tissue samples from the same patients, 
sequentially obtained (see text). 
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of chromosome 1 or Y. Gain of chromosome 18 oc- 
curred in more than half of the cases, but the cut-off 
percentage set through the results obtained with BPH 
specimens was lowest for chromosome 18. Further- 
more, the presence of trisomic cells together with tet- 
rasomy for chromosomes 1 and 18 was a common 
finding. Both the finding of minor polysomic cell 
populations and the observation of trisomic and tet- 
rasomic cells together in the same tumor specimens 
are in agreement with the generally accepted theory 
that the genetic evolution of solid tumors converges 
on repeated rounds of tetraploidization and subse- 
quent chromosome loss [24]. Following this concept, 
minor fractions of cells which show gain of hybrid- 
ization signals are thought to be a manifestation of 
the onset of tetraploidization of a tumor [25]. 
An explanation for the lower frequency of gain for 
Y could be that relative loss of one Y chromosome in 
a tetraploid tumor cell will result in monosomy for Y, 
thereby making this cell indistinguishable from a dip- 
loid cell. Simultaneous loss and gain of a chromo- 
some in the same specimen, indicative for heteroge- 
neous changes, was rare for chromosomes 1 and 18 
(respectively, one and two cases) and occurred in 
16% of the cases investigated with the Y probe. 
The correlation between DNA-FCM and FISH was 
less strong than expected. Surprisingly, most DNA 
diploid tumors showed significant gain of one or 
more of the investigated chromosomes. Apparently, 
already in diploid tumors additional copies of espe- 
cially chromosome 18 could be present without being 
detected by DNA-FCM. On the other hand, an an- 
euploid DNA histogram did not imply the presence 
of numerical aberrations for all three investigated 
chromosomes. However, as expected, with an in- 
creasingly aberrant and complex histogram, more of 
the investigated chromosomes became aberrant. 
The occurrence of numerical aberrations in the 
three investigated chromosomes was independent of 
tumor grade or stage, nor was there a correlation be- 
tween the presence of aberrations in each individual 
chromosome and grade or stage (not shown). How- 
ever, as expected, the DNA-FCM of a tumor was 
more likely to be abnormal with increasing grade and 
stage. At present two other studies report the detec- 
tion of numerical chromosomal aberrations with cen- 
tromere-specific probes in PC [26, 271. The first study 
investigated chromosomes 7, 17, X, and Y on paraffin 
sections. Although this method will lead to an under- 
estimation of the number of in situ signals, due to the 
loss of nuclear material [28], aberrations were found 
in 5/11 investigated tumors. These tumors were all of 
advanced stage or grade with a large tumor volume. 
No details were presented on specific chromosomal 
aberrations found, but some heterogeneity with re- 
spect to different regions in the tumor area was re- 
ported. The other study used cells obtained from tis- 
sue cultures of 10 PC specimens. The copy numbers 
of chromosomes 7,8,10,16,17, and 18 were assessed 
by FISH. Frequent losses and gains were observed for 
all chromosomes investigated. However, culturing 
artifacts, caused by preferential growth of subgroups 
of tumor cells, or even normal cells [S], cannot be 
ruled out. Unfortunately, as demonstrated by the 
high percentages of nuclei with 0 and 1 spot, the 
specificity of the hybridizations was rather low, mak- 
ing it difficult to draw any definite conclusions from 
these data. 
In bladder carcinoma, FISH studies [25, 291 have 
shown numerical aberrations for chromosome 1 in 
20-25% of the cases, and also in breast cancer aber- 
rations of chromosome 1 were shown to occur [30]. 
Cytogenetic studies on PC have shown that chromo- 
some 1, when aberrant, is most frequently structur- 
ally rearranged [3, 4, 311. In PC cell lines, gain of 
chromosome 1 is also common [32-361. The relatively 
common gain of chromosome 1 we report here is in 
agreement with these results. 
Cytogenetically, chromosome 18 was not shown to 
be nonrandomly or specifically affected in PC, but in 
two LOH studies, loss of loci on the long arm of 
chromosome 18 was reported in 3/7 [15] and 2/12 [16] 
informative cases. Our data showed that complete 
loss of one homolog was infrequent, but that gain 
was common. Chromosomal duplication, driven by 
gene loss, could be a possible mechanism behind this 
observation. 
Loss of Y is a recurrent chromosomal aberration in 
PC [l-3,5,17], sometimes found as the sole anomaly. 
Also with in situ hybridization on paraffin sections 
some PCs were shown to have loss of Y [27, 371. The 
frequency of 53% we found in the present study is 
quite high, but could be biased by the low cut-off 
percentage derived from the studies in BPH speci- 
mens, which served as a control. The loss of Y has 
been described, not only in other solid tumors but 
also in benign and normal tissues. So, on the other 
hand, loss of the Y chromosome may also reflect a 
general state of tissue hyperproliferation and as such 
may not exclusively be related to neoplastic pro- 
cesses. 
The finding that gain of chromosomes 1 and Y was 
restricted to DNA aneuploid tumors is not surprising. 
However, we have no explanation for the almost con- 
sistent finding of a higher percentage of disomic 
(monosomic for Y) cells in aneuploid tumors than 
was to be expected on the basis of DNA ploidy. Al- 
though applied on the same isolated cells, the sensi- 
tivity of the techniques appears to be different. By 
FISH the percentage of aneusomic nuclei seldom 
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reached 30%, while with DNA-FCM the percentage 
of aneuploid nuclei could be over 90%. This phenom- 
enon was observed before in PC and bladder carci- 
noma in comparative studies using FISH and DNA- 
FCM [8, 22, 291. A similar effect has been described 
recently in a comparative study of cytogenetic and 
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TABLE IV. Relationship Between Stage, Numerical 
Aberrations, and Ploidy 
% Aberration % Aberration 
Stage No. (FISH) (FCW 
- T I  0 
T2 7 86 
T3 16 88 
T4 19 84 
- 
43 
63 
79 
TABLE V. Relationship Between Grade, Numerical 
Aberrations, and Ploidy 
~~ ~ 
% Aberration % Aberration 
Grade No. (FISH) (FCM) 
1 5 80 
2 16 88 
3 21 86 
60 
50 
81 
Fig. 2. Examples of spot distribution of chromosomes I, 18, and 
Y and FCM analysis in A a DNA diploid tumor (PC352); B a DNA 
tetraploid tumor (PC355); C: a tumor with multiple aneuploid 
stemlines (PC290); and D: a DNA hypodiploid tumor (PC269). * = 
above cut-off value. 
DNA-FCM data on bone and soft tissue tumors [38]. 
In karyotypically abnormal tumors which were an- 
euploid, a tendency towards DNA indices higher 
than the chromosomal index was reported. This was 
partly explained by the assumption that in these tu- 
mors, which often had complex chromosomal rear- 
rangements, the size of some marker chromosomes 
probably exceeded the size of normal homologs. This 
could also be the case for PCs which show moderate 
differences, but still cannot explain the large discrep- 
ancies found in some highly aneuploid tumors. 
The correlation between tumor ploidy and tumor 
aggressiveness has been well established [9-121. Re- 
cently, Lundgren et al. [311 showed the association of 
the presence of clonal chromosomal aberrations with 
an unfavorable outcome in PC patients. In the 
present study we found that the presence of numer- 
ical aberrations of the chromosomes we investigated 
was unrelated to tumor grade or stage. 
In conclusion, the results obtained with FISH of 
only three centromere-specific probes show signifi- 
cant aneuploidy in small subpopulations in a total of 
about 90% of the investigated tumors. This is in con- 
trast with FCM where 63% of the tumors show an 
aneuploid peak. Both the results obtained with FISH 
and with FCM indicate that cytogenetic studies of PC 
after short-term tissue culture selectively have pro- 
duced karyotypic data on the normal cell component 
of the tumor. Therefore, to gain more insight into the 
cytogenetic composition of PC, FISH studies of all 
relevant (parts of) chromosomes appears for the time 
being the technology of choice. 
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